Michael Davidson, M.D.
Principal executive officer pay for Michael Davidson, M.D., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
NewAmsterdam Pharma Co N.V. (NAMS) FY2023–FY2025
Beat peersTSR 214% vs peer group 30% over FY2023–FY2025
Turnaround$100 invested moved from behind the peer group ($102.48 vs $104.59) to ahead ($321.83 vs $135.46) over FY2023–FY2025
Aligned: paid up as stock roseCAP $4,717,541→$30,500,720 while $100 invested went $102.48→$321.83
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $5.8M | $4.7M |
| FY2024 | $6.5M | $49.5M |
| FY2025 | $13.6M | $30.5M |
The company's "$100 invested" index ran $102.48 at FY2023 → $321.83 by FY2025 — an annualized return of 77.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 77.2%/yr at NAMS ( FY2023–FY2025). See the CEO track-record ranking for context.